Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has agreed a put option to sell: (i) its 5% economic interest in the commercialisation of
Cizzle Biotechnology plc (LON:CIZ), the UK-based diagnostics developer, notes the announcement by Conduit Pharmaceuticals Limited that they intend to become a publicly traded company on NASDAQ in the USA via
Cizzle Biotechnology Holdings PLC (LON:CIZ), the UK based diagnostics developer, has announced its interim results for the six months ended 30 June 2022. Highlights · On 14 February 2022 the Group announced
Cizzle Biotechnology plc (LON:CIZ), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for the early detection of different forms of
Cizzle Biotechnology plc (LON:CIZ), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for the early detection of different forms of
Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has provided an update on the Company’s progress to develop antibodies for use in its proprietary early lung cancer tests, and
Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced that it has entered into an agreement with the Behnke Group, a Texas-based healthcare consulting firm with decades of
Cizzle Biotechnology plc (LON:CIZ), the UK-based diagnostics developer, has announced that copies of the annual report and accounts for the year ended 31 December 2021, together with the notice of Annual
Cizzle Biotechnology plc (LON:CIZ), the UK-based diagnostics developer, has announced its audited results for the year ended 31 December 2021. Chair’s Statement I am pleased to report on the Group’s activities
Cizzle Biotechnology Holdings plc (LON:CIZ) Executive Chairman, Allan Syms joins DirectorsTalk Interviews to discuss an agreement with CorePath Laboratories to develop and offer its proprietary early-stage lung cancer test throughout the
© 2022 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
